Article Sidebar
Published:
Sep 6, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of lipoic acid combination with valsartan on diabetic nephropathy and associated adverse reactions
Abstract
Purpose: To investigate the effect of lipoic acid combination with valsartan on diabetic nephropathy (DN) and its associated adverse reactions.
Methods: A retrospective analysis was conducted on 120 patients who treated for DN at the Second Affiliated Hospital of Shenzhen University, China between August 2019 and October 2022. Based on different treatment approaches, control group comprised 55 patients receiving valsartan alone, while joint group consisted of 65 patients receiving a combination of valsartan and lipoic acid. Therapeutic effectiveness and adverse events were compared between the groups. Additionally, changes in blood glucose and renal function parameters were evaluated pre- and post-treatment.
Results: Post-treatment, both groups exhibited improvements in blood glucose and renal function parameters compared to pre-treatment values (p < 0.05). However, joint group demonstrated superior improvements in these parameters compared to control group (p < 0.05). Total efficacy was significantly higher in the joint group than in control group (p < 0.05). No significant differences were observed between the groups' incidence of adverse reactions (p > 0.05).
Conclusion: Concurrent therapy of lipoic acid and valsartan sly treats DN. It enhances the regulation of blood glucose levels and improves renal function with high safety. Further studies employing larger sample sizes and prospective designs with comprehensive patient follow-up are required to further validate and enhance the reliability of these findings.
